Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 20
- Registration Number
- NCT03209648
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03174041
- Locations
- 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
🇺🇸Covance Clinical Research Unit Inc.; Covance Gfi Research, Evansville, Indiana, United States
🇺🇸Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 10
- Registration Number
- NCT03173170
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc., Lenexa, Kansas, United States
A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03161405
- Locations
- 🇺🇸
Takeda Investigational Site, Lenexa, Kansas, United States
A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT03135106
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT03119077
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Drug-drug Interaction (DDI) With a P-gp Inhibitor, Organic Anion Transporting Polypeptide OATP-inhibitor, Food Effect
- Conditions
- Interventions
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT03116893
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Proof-of-Concept Superiority Trial of Fosravuconazole Versus Itraconazole for Eumycetoma in Sudan
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 104
- Registration Number
- NCT03086226
- Locations
- 🇸🇩
Mycetoma Research Centre, Khartoum, Sudan
A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-16
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 13
- Registration Number
- NCT03081702
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT03077607
- Locations
- 🇲🇩
ARENSIA Exploratory Medicine Phase I Unit, PMSI Institute of Oncology, Chisinau, Moldova, Republic of
🇷🇺"BioEq" LLC, Saint-Petersburg, Russian Federation
🇷🇺I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.